Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic variation in targets of lipid-lowering drugs and amyotrophic lateral sclerosis risk: a Mendelian randomization study.

Amyotrophic lateral sclerosis & frontotemporal degeneration - 1 Feb 2024

Li Zhiguang, Tian Mei, Jia Hongning, Li Xin, Liu Qi, Zhou Xiaomeng, Li Rui, Dong Hui, Liu Yaling

Abstract excerpt

BACKGROUND: The use of lipid-lowering drugs is still highly controversial in patients with amyotrophic lateral sclerosis (ALS). We performed a drug-target Mendelian randomization (MR) analysis to investigate the effect of targeted lipid-lowering drugs on the risk of ALS. METHODS: First, we evaluated the causal relationship between HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase (HMGCR) inhibitors-taking...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amyotrophic Lateral Sclerosis
Share to Apolipoproteins B

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cholesterol, LDL

Share to HMGCR gene

Share to Genetic Variation

Share to Genome-Wide Association Study

Share to Mendelian Randomization Analysis

Share to Polymorphism, Single Nucleotide

Source

Identifiers

PMID: 37688479
DOI: 10.1080/21678421.2023.2255622

Genes

HMGCR
APOB

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic variation in targets of lipid-lowering drugs and amyotrophic lateral sclerosis risk: a Mendelian randomization study.PMID 37688479Read ↗

Mendelian Randomization Analysis Reveals Statins Potentially Increase Amyotrophic Lateral Sclerosis Risk Independent of Peripheral Cholesterol-Lowering EffectsSemantic proximity Read ↗

Discovery and Exploration of Lipid-Modifying Drug Targets for ALS by Mendelian Randomization.Semantic proximity Read ↗

Association between genetically proxied lipid-lowering drug targets, lipid traits, and amyotrophic lateral sclerosis: a mendelian randomization study.Semantic proximity Read ↗

Lipids and amyotrophic lateral sclerosis: A two-sample Mendelian randomization study.Semantic proximity Read ↗

Causal effects of blood lipids on amyotrophic lateral sclerosis: a Mendelian randomization studySemantic proximity Read ↗

Atorvastatin, simvastatin, rosuvastatin and Amyotrophic lateral sclerosis establishing cause and effectSemantic proximity Read ↗

Genetic insights of lipid metabolism and lipid-lowering drugs with Lewy body dementia risk: Evidence from Mendelian randomization.Semantic proximity Read ↗

Genetic Associations of Lipid-Lowering Drugs and Parkinson’s Disease: A Mendelian Randomization StudySemantic proximity Read ↗

Identification of lipid-modifying drug targets for autoimmune diseases: insights from drug target mendelian randomization.Semantic proximity Read ↗

Assessing the role of blood pressure in amyotrophic lateral sclerosis: a Mendelian randomization study.Semantic proximity Read ↗

Potential Correlation between Tea Intake and the Risk of Amyotrophic Lateral Sclerosis: A Mendelian Randomization Study.Semantic proximity Read ↗

A review of Mendelian randomization in amyotrophic lateral sclerosisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.